NUVECTIS PHARMA INC (NVCT)

US67080T1088 - Common Stock

10.67  -0.31 (-2.82%)

After market: 10.14 -0.53 (-4.97%)

Fundamental Rating

2

NVCT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. While NVCT has a great health rating, there are worries on its profitability. NVCT is valued expensive and it does not seem to be growing.



0

1. Profitability

1.1 Basic Checks

NVCT had negative earnings in the past year.
In the past year NVCT has reported a negative cash flow from operations.

1.2 Ratios

Looking at the Return On Assets, with a value of -111.94%, NVCT is doing worse than 79.50% of the companies in the same industry.
Looking at the Return On Equity, with a value of -176.27%, NVCT is doing worse than 66.84% of the companies in the same industry.
Industry RankSector Rank
ROA -111.94%
ROE -176.27%
ROIC N/A
ROA(3y)-134.37%
ROA(5y)N/A
ROE(3y)-206.9%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

NVCT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, NVCT has more shares outstanding
There is no outstanding debt for NVCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

NVCT has an Altman-Z score of 11.63. This indicates that NVCT is financially healthy and has little risk of bankruptcy at the moment.
NVCT's Altman-Z score of 11.63 is amongst the best of the industry. NVCT outperforms 85.56% of its industry peers.
There is no outstanding debt for NVCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 11.63
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

NVCT has a Current Ratio of 2.74. This indicates that NVCT is financially healthy and has no problem in meeting its short term obligations.
NVCT has a worse Current ratio (2.74) than 68.09% of its industry peers.
NVCT has a Quick Ratio of 2.74. This indicates that NVCT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.74, NVCT is doing worse than 66.49% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.74
Quick Ratio 2.74

1

3. Growth

3.1 Past

NVCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.38%, which is quite impressive.
EPS 1Y (TTM)21.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

NVCT is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.58% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y26.67%
EPS Next 2Y13.27%
EPS Next 3Y6.58%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

NVCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NVCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.27%
EPS Next 3Y6.58%

0

5. Dividend

5.1 Amount

No dividends for NVCT!.
Industry RankSector Rank
Dividend Yield N/A

NUVECTIS PHARMA INC

NASDAQ:NVCT (11/13/2024, 4:42:55 PM)

After market: 10.14 -0.53 (-4.97%)

10.67

-0.31 (-2.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap206.14M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -111.94%
ROE -176.27%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.74
Quick Ratio 2.74
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)21.38%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y26.67%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y